Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This review summarizes multisystem late effects after pediatric CNS tumor treatment and discusses surveillance, complication-mitigation, risk-adapted follow-up, multidisciplinary survivorship care, and transition to adult care.
The supplied review supports the clinical premise that personalized, multidisciplinary, risk-stratified surveillance may improve recognition and management of treatment-related morbidity; however, any claim that specific survivorship interventions improve long-term outcomes remains an inference because no comparative intervention results are reported.
This review synthesizes epidemiology, manifestations, diagnostic approaches, treatment regimens, complications, and prevention of miliary tuberculosis, including CNS-directed therapy, drug-resistant disease, TB-IRIS management, and BCG protection in children.
The supplied review supports established antimicrobial, corticosteroid, diagnostic, and vaccination strategies for miliary tuberculosis; it is reasonable—but untested here—to infer that heightened recognition and optimized diagnosis could benefit immunocompromised pediatric oncology patients, while no cancer-specific therapeutic strategy is evaluated.
In a multicenter cross-sectional cohort of 87 anti-TNF-treated Crohn’s disease patients aged 1–22 years, lower CD64 biomarkers and slower infliximab clearance were associated with endoscopic healing, while anti-TNF trough concentrations were not.
The study provides associative evidence that infliximab clearance and CD64-based pharmacodynamic biomarkers may distinguish patients with endoscopic healing; if prospectively validated, these measures could potentially guide anti-TNF dose escalation versus switching therapy, but no oncology application or clinical benefit from biomarker-guided treatment was tested.
Using SEER and Optum electronic health record data from 2017–2021, the study applied five candidate anthropometric or diagnostic-code criteria to 26,855 children with cancer and found that estimated cachexia prevalence and incidence varied substantially by definition, age, and cancer type.
The study provides observational evidence for a framework to identify potential pediatric cancer cachexia; it is reasonable but unproven to infer that validated consensus criteria could enable earlier nutritional or supportive-care intervention and improve research stratification, as no treatment effect or clinical outcome benefit was tested.
The study reports that MAGIBU, a projection- and proximity-based DNA methylation decision-support framework, showed high agreement with a predefined classifier consensus in eight diagnostically unresolved pediatric/juvenile CNS tumors and was additionally assessed across larger methylation datasets and non-array platforms.
Evidence: MAGIBU may complement existing methylation classifiers by providing quantitative differential diagnoses for ambiguous CNS tumors; inference: if prospectively validated against independently established diagnoses and clinical outcomes, improved classification could support more appropriate treatment selection and reduce misclassification-related toxicity, but no therapeutic intervention or outcome benefit is demonstrated here.
This review synthesizes genetic, metabolic, and clinical evidence on pediatric hyperuricemia, including its evaluation and indication-based management in settings such as inherited disorders, kidney disease, nephrolithiasis, gout, and tumor lysis syndrome.
The supplied review supports early etiologic evaluation and indication-specific management of hyperuricemia in children; it is reasonable to hypothesize that genetically and clinically stratified urate-lowering interventions could reduce renal or metabolic complications, but the record does not provide pediatric comparative-treatment evidence establishing that benefit.
This narrative review synthesizes evidence for diffusion-weighted MRI as an adjunct in musculoskeletal diagnosis, tumor characterization, staging, and treatment-response assessment, while emphasizing tissue-composition and technical pitfalls that limit ADC interpretation.
The reviewed evidence supports DWI as a complementary imaging biomarker for assessing response in bone and soft-tissue sarcomas; it is reasonable—but not established by this review—to hypothesize that validated DWI measures could enable earlier treatment adaptation in pediatric oncology without constituting a therapy themselves.
In a longitudinal cohort of 1,081 five-year childhood cancer survivors assessed twice over a median 17 years, persistent sleep disturbances were associated with new-onset hypertension, migraines, and emotional distress, but not subsequent malignancies.
The study provides observational evidence that persistent sleep disturbance identifies survivors at elevated risk for selected chronic and mental health conditions; it is reasonable—but unproven—to hypothesize that early sleep screening and effective sleep-directed interventions could reduce these risks or improve long-term well-being.
Untargeted LC-MS profiling of bone marrow aspirates from 21 children with B-lineage ALL identified metabolite patterns distinguishing nine samples obtained at relapse from 12 samples obtained at initial diagnosis, highlighting carnitine, amino-acid, and lipid metabolism for further study.
Evidence: relapse-phase marrow showed altered metabolite abundances, including elevated O-acetylcarnitine and L-allo-threonine and decreased AMP. Inference: if independently validated and functionally linked to leukemia-cell survival, fatty-acid oxidation, serine-glycine one-carbon metabolism, or ether-lipid metabolism could provide biomarkers or therapeutic vulnerabilities in relapsed ALL; this study does not establish pathway activity, causality, drug sensitivity, or clinical benefit.
This mini-review synthesizes indirect evidence that developmental programs, extracellular-matrix remodeling, hypoxia, and cancer stem-cell plasticity may converge on integrin β1 signaling to influence medulloblastoma progression and therapy resistance.
The supplied evidence identifies integrin β1 as an underexplored candidate regulator rather than a validated target; it can be hypothesized that disrupting integrin β1-dependent tumor–matrix signaling could reduce stemness or therapy resistance in medulloblastoma, but direct efficacy, safety, and clinical evidence are not reported.
In a retrospective cohort of 269 children with NF1, 11 had imaging-defined brainstem lesions that were predominantly stable or regressed under observation, while one child underwent endoscopic third ventriculostomy for lesion-associated obstructive hydrocephalus with symptomatic improvement.
The reported outcomes support observation rather than routine active intervention for clinically stable NF1-associated brainstem lesions; it can be inferred—but not established from this small retrospective series—that surveillance-based management may avoid unnecessary treatment while reserving symptom-directed procedures for complications such as hydrocephalus.
This case report describes a 13-year-old with B-ALL who developed abrupt fever followed by seizures, coma, diffuse cerebral edema, and irreversible neurological decline on day 13 of a second blinatumomab cycle despite prior treatment tolerance and prompt drug discontinuation and dexamethasone.
The reported case supports a safety hypothesis—not a proven mechanism—that delayed, fever-associated catastrophic neurotoxicity can occur during later blinatumomab exposure; if confirmed in larger studies, risk biomarkers and extended neurological monitoring could enable earlier intervention or treatment modification.
